Is Amoxicillin Good for Treating COVID-19?

Amoxicillin does not treat COVID-19. It is an antibiotic, and antibiotics work against bacteria, not viruses. Since COVID-19 is caused by the SARS-CoV-2 virus, amoxicillin has no ability to slow the virus down, kill it, or shorten your illness. Yet amoxicillin was one of the most prescribed drugs during the pandemic, a contradiction that created real consequences for patients and public health alike.

Why an Antibiotic Cannot Fight a Virus

Amoxicillin belongs to the penicillin family. It works by interfering with the construction of bacterial cell walls, which causes bacteria to burst and die. Viruses do not have cell walls. They are structurally different from bacteria in almost every way that matters for drug design: they hijack your own cells to replicate, they lack the metabolic machinery that most antibiotics target, and they are orders of magnitude smaller. No antibiotic on the market, amoxicillin included, has any direct effect on SARS-CoV-2. Treating a viral infection with an antibiotic is like trying to put out an electrical fire with a bucket of sand meant for a campfire. The tools simply do not match the problem.

How Amoxicillin Ended Up Being Prescribed Anyway

Despite the mismatch, antibiotics were handed out at staggering rates during the pandemic. A study of COVID-19 outpatients found that at least one antibiotic was prescribed to about 91% of them in 2020, dropping to roughly 83% in 2021 and 74% in the first half of 2022. The three most commonly prescribed were azithromycin, amoxicillin/clavulanic acid (a combination that pairs amoxicillin with a drug that helps it overcome certain resistant bacteria), and doxycycline.¹ A national analysis of over 600,000 hospital admissions across more than 800 U.S. hospitals confirmed that while antibiotic prescribing for COVID-19 patients has declined since the early pandemic, unnecessary use remains common, particularly in intensive care and intermediate care settings where disease severity drives clinical decision-making.²

Several factors fueled the overprescribing. A systematic review and meta-analysis examining hospitalized COVID-19 patients pointed to limited testing facilities, a lack of awareness, overwhelmed hospitals, and clinicians who simply had no experience managing a pandemic of this scale.³ Early in 2020, doctors often could not tell quickly whether a patient’s pneumonia was purely viral or had a bacterial component. The safest-feeling option, in a chaotic and unfamiliar setting, was to cover for bacteria “just in case.” That instinct is understandable, but it led to enormous volumes of unnecessary antibiotic use.

When Antibiotics Are Actually Appropriate for a COVID-19 Patient

There is a narrow but real scenario where amoxicillin or a related antibiotic makes sense for someone who has COVID-19: when a secondary bacterial infection develops on top of the viral illness. COVID-19 can damage lung tissue and weaken immune defenses in ways that let bacteria move in. If a patient with COVID-19 develops bacterial pneumonia, a urinary tract infection, or a bloodstream infection, antibiotics become necessary to treat that separate bacterial problem.

International guidelines drew this line clearly. The World Health Organization recommended no antibiotic therapy or preventive antibiotics for patients with mild or moderate COVID-19 unless signs and symptoms of a bacterial infection exist, and for severe cases, daily reassessment for stepping down any antibiotics already started. The UK’s National Institute for Health and Care Excellence issued similar guidance: do not use antibiotics for preventing or treating COVID-19, and only prescribe them if there is strong clinical suspicion of an additional bacterial infection.⁴ Malaysian national prescribing data reflected this approach in practice: when bacterial co-infection was suspected during viral pneumonia, the first-line choice was amoxicillin/clavulanic acid, with escalation to broader antibiotics like piperacillin/tazobactam reserved for more serious cases.⁵

The critical distinction is that in these cases, the antibiotic is treating the bacterial co-infection, not the COVID-19 itself. Amoxicillin does nothing to the virus. It is addressing a complication that the virus helped create.

How Doctors Can Tell If Bacteria Are Involved

One of the hardest parts of managing COVID-19 patients, especially early in the pandemic, was figuring out whether a worsening patient had a bacterial infection layered on top of the virus or was simply getting sicker from the virus alone. Both can look similar: fever, worsening breathing, abnormal chest imaging, elevated inflammatory markers. This ambiguity is a big reason so many antibiotics were prescribed “just in case.”

A blood test called procalcitonin emerged as a useful tool for sorting this out. Procalcitonin levels tend to rise in bacterial infections but stay relatively low during purely viral illness. A quality improvement project at a UK hospital found that when COVID-confirmed patients had low procalcitonin (below 0.25 micrograms per liter), antibiotics were either never started or stopped within 48 hours in about 72% of cases. The authors concluded that procalcitonin testing, combined with thorough clinical assessment, offered a safe and sustainable way to cut antibiotic use in COVID-19.⁶ Research in cancer patients admitted with COVID-19 reinforced the finding: those with low procalcitonin were far less likely to have a positive bacterial culture than those with elevated levels, and a low reading had a high negative predictive value for both bloodstream infection and death within 30 days.⁷

Wider adoption of procalcitonin testing could have spared many patients from unnecessary courses of amoxicillin and other antibiotics. The test is not perfect, and clinical judgment still matters, but it offered a concrete way to reduce guesswork.

The Azithromycin Lesson

If you are wondering whether any antibiotic was formally tested against COVID-19 in a rigorous trial, the answer is yes, but not amoxicillin. Azithromycin, a different antibiotic that also has some anti-inflammatory properties, was the one that got a proper clinical evaluation. It was a reasonable candidate to test because, beyond its antibacterial activity, azithromycin has mild antiviral and immunomodulatory effects that researchers thought might help.

The PRINCIPLE trial in the UK, a large randomized controlled trial involving people at increased risk of COVID-19 complications, tested azithromycin added to usual care versus usual care alone. The result was clear: there was little evidence of a meaningful benefit. Adding azithromycin shortened recovery by less than a day on average, and the probability that the benefit reached a clinically meaningful threshold was only about 23%. Hospitalization rates were essentially the same in both groups, around 3%. The researchers concluded that the findings did not justify routine use of azithromycin for reducing time to recovery or risk of hospitalization in people with suspected COVID-19 in the community.⁸

No comparable trial was conducted for amoxicillin, because there was never a plausible mechanism by which it might help against the virus. Azithromycin at least had theoretical anti-inflammatory and antiviral properties worth testing. Amoxicillin does not. The azithromycin result, showing no benefit even for an antibiotic with possible extra tricks, makes the case against using ordinary antibiotics like amoxicillin for COVID-19 even stronger.

What Actually Treats COVID-19

COVID-19 is a viral disease and requires antiviral treatment, not antibacterial. The antiviral nirmatrelvir/ritonavir (marketed as Paxlovid) became one of the most important outpatient treatments for COVID-19, particularly for people at risk of severe disease. Interestingly, prescribing Paxlovid also appeared to reduce unnecessary antibiotic use. A large study comparing over 67,000 patients treated with nirmatrelvir/ritonavir against nearly 235,000 who were not found that treated patients were about 35% less likely to receive an outpatient antibiotic prescription. Much of this appeared to be driven by a reduced perceived need for “just in case” antibiotic coverage when a proper antiviral was already on board.⁹

Beyond Paxlovid, other antivirals like remdesivir and molnupiravir were authorized for COVID-19 treatment in various clinical settings. Corticosteroids such as dexamethasone proved life-saving for hospitalized patients requiring supplemental oxygen by dampening the overactive immune response that causes much of the damage in severe COVID-19. Monoclonal antibodies were also used earlier in the pandemic, though most lost effectiveness as new variants emerged. None of these are antibiotics. Every treatment that has shown genuine benefit against COVID-19 targets either the virus itself or the body’s damaging immune overreaction, not bacteria.

The Antibiotic Resistance Fallout

The mass prescribing of antibiotics during the pandemic was not a harmless precaution. It carried real consequences. A systematic review and meta-analysis examining antibiotic resistance trends during the COVID-19 pandemic found that the lack of antimicrobial stewardship programs and infection-control reporting was significantly associated with increased resistance among gram-negative bacteria.¹⁰ Hospitals that maintained stewardship and infection-control efforts did not see the same rise in resistance, which underscores that the problem was not inevitable but rather a consequence of how antibiotics were used.

Separately, prior antimicrobial use and the rate of hospital-acquired infections both rose significantly during the pandemic.¹¹ In other words, the pandemic created a feedback loop: overwhelmed hospitals prescribed more antibiotics, which bred more resistant bacteria, which caused more hospital-acquired infections that required even stronger antibiotics. Amoxicillin, as one of the most commonly prescribed antibiotics during this period, was part of this cycle.

What Unnecessary Amoxicillin Does to Your Body

Even setting aside population-level resistance, taking amoxicillin when you do not have a bacterial infection is not cost-free for you as an individual. Every course of amoxicillin disrupts your gut microbiome. Research published in The Lancet Microbe tracked what happened to the gut bacteria of children given amoxicillin versus a placebo. Within a week of starting amoxicillin, gut microbiome richness dropped from an average of about 38 species to 28 species, and microbial diversity fell substantially. The abundance of Proteobacteria, a group that includes many pathogenic species, roughly doubled. Perhaps most concerning, the number of antibiotic resistance genes in the gut shot up immediately. Amoxicillin-treated children carried a median of about 77 resistance genes at week one compared to 52 in the placebo group.¹²

The good news from that study was that the resistance gene increase appeared to be transient, returning toward baseline about three weeks after the course ended. But “transient” in a study setting does not necessarily mean risk-free in the real world. During the window of disruption, a person’s gut harbors bacteria that are more resistant and more likely to include potentially harmful species. If you pick up a secondary infection during that window, it could be harder to treat. Multiply this across millions of people taking unnecessary amoxicillin for COVID-19, and the scale of the problem becomes clear.

Beyond resistance, common side effects of amoxicillin itself include diarrhea, nausea, and skin rashes. Allergic reactions, though uncommon, can be serious. These are risks worth taking when you genuinely have a bacterial infection that needs treatment. They are not worth taking for a viral illness where the drug provides zero benefit.

Why People Still Ask for Antibiotics When They Have COVID

Part of the reason amoxicillin keeps coming up in conversations about COVID-19 is that many people have a deeply ingrained association between “feeling very sick” and “needing antibiotics.” For decades before the pandemic, antibiotics were overprescribed for colds, flu, bronchitis, and other viral illnesses. That pattern trained a generation to believe that antibiotics are the appropriate response to any serious respiratory illness. When COVID-19 arrived as the most frightening respiratory illness most people had ever encountered, the reflex to reach for antibiotics was understandably strong.

Doctors also faced pressure. In an uncertain and rapidly evolving situation, with patients deteriorating and limited diagnostic tools available, prescribing an antibiotic felt like doing something. The psychological weight of potentially withholding treatment from a critically ill patient is enormous, even when the evidence says the treatment will not help. This dynamic played out in hospitals worldwide, and amoxicillin/clavulanic acid was one of the go-to choices simply because it is a familiar, broadly effective, and inexpensive antibiotic that covers common respiratory bacteria.

The prescribing rates did gradually improve. The drop from 91% of outpatients receiving antibiotics in 2020 to about 74% by mid-2022 suggests that clinical education, updated guidelines, and better diagnostic tools like procalcitonin testing made a difference over time.¹ But those numbers remain high for a disease where the vast majority of patients have no bacterial co-infection.

What to Do If You Have COVID-19 and Are Offered Amoxicillin

If a doctor prescribes you amoxicillin while you have COVID-19, it is worth asking a direct question: is there evidence of a bacterial infection, or is this precautionary? If there are clear signs of bacterial co-infection, such as a positive bacterial culture, elevated procalcitonin, or clinical findings strongly suggesting bacterial pneumonia, then the antibiotic makes sense. It is treating the bacterial problem, not the virus.

If the prescription is precautionary and there is no concrete evidence of bacteria, it is reasonable to discuss whether watchful waiting or a procalcitonin test might be a better first step. You are not being difficult by asking. The WHO, NICE, and virtually every major infectious disease guideline agrees that antibiotics should not be used for COVID-19 unless a bacterial infection is documented or strongly suspected. Taking amoxicillin “just in case” when you have COVID-19 exposes you to side effects and gut disruption with no offsetting benefit against the virus.

If your symptoms worsen after a few days, particularly with new fever, productive cough with discolored sputum, or increasing shortness of breath, that is a different conversation. Bacterial superinfection can develop as a complication of COVID-19, and catching it early matters. The point is not to refuse antibiotics categorically but to make sure they are being used for the right reason at the right time.